Tag: SENZA-PDN
Two-year data indicate long-term effectiveness of Nevro’s SCS therapy in painful...
Nevro Corporation recently announced the publication of 24-month data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—the largest RCT to evaluate...
Nevro announces two late-breaking data presentations set for NANS 2023
Nevro Corporation has announced that two abstracts for clinical trials relating to painful diabetic neuropathy (PDN) and non-surgical back pain (NSBP) treatments have been...
High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes
Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...
High responder rates, substantial pain relief and no explants among key...
Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
Nevro announces upcoming presentation of new SENZA-PDN clinical data
Nevro Corporation has announced that data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—which the company says is the largest RCT to...
